DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma., Molecular and Cellular Biology, vol.14, issue.5, pp.3230-3241, 1994. ,
DOI : 10.1128/MCB.14.5.3230
Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2 and c-Myc expression, Oncogene, vol.20, issue.25, pp.3258-3265, 2001. ,
DOI : 10.1007/BF02281873
Upregulation of Id2, an oncogenic helix-loop-helix protein, is mediated by the chimeric EWS/ets protein in Ewing sarcoma, Oncogene, vol.22, issue.1, pp.1-9, 2003. ,
DOI : 10.1038/17812
Downregulation and forced expression of EWS-Fli1 fusion gene results in changes in the expression of G1regulatory genes, British Journal of Cancer, vol.84, issue.6, pp.768-775, 2001. ,
DOI : 10.1054/bjoc.2000.1652
GLI1 Is a Direct Transcriptional Target of EWS-FLI1 Oncoprotein, Journal of Biological Chemistry, vol.269, issue.14, pp.9074-9082, 2009. ,
DOI : 10.1158/0008-5472.CAN-07-0491
Identification of target genes for the Ewing's sarcoma EWS/FLI fusion protein by representational difference analysis., Molecular and Cellular Biology, vol.15, issue.8, pp.4623-4630, 1995. ,
DOI : 10.1128/MCB.15.8.4623
Vascular Endothelial Growth Factor Expression is Up-Regulated by EWS-ETS Oncoproteins and Sp1 and May Represent an Independent Predictor of Survival in Ewing's Sarcoma, Clinical Cancer Research, vol.10, issue.4, pp.1344-1353, 2004. ,
DOI : 10.1158/1078-0432.CCR-03-0038
EWS/Fli-1 chimeric fusion gene upregulates vascular endothelial growth factor-A, International Journal of Cancer, vol.23, pp.2790-2798, 2010. ,
DOI : 10.4161/cbt.2.2.348
URL : http://onlinelibrary.wiley.com/doi/10.1002/ijc.24781/pdf
The orphan nuclear receptor DAX1 is up-regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors, International Journal of Cancer, vol.16, issue.6, pp.1381-1389, 2006. ,
DOI : 10.1210/me.16.3.515
URL : https://hal.archives-ouvertes.fr/hal-00172274
DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells, Oncogene, vol.275, issue.46, pp.6034-6043, 2008. ,
DOI : 10.1128/MCB.17.3.1476
FOXM1 Is an Oncogenic Mediator in Ewing Sarcoma, PLoS ONE, vol.103, issue.1, p.54556, 2013. ,
DOI : 10.1371/journal.pone.0054556.s004
EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation, Proceedings of the National Academy of Sciences, vol.4, issue.5, pp.5324-5329, 2009. ,
DOI : 10.1038/nm0598-627
Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FlI1 oncoprotein, Nat Genet, vol.23, pp.222-227, 1999. ,
as a Direct Target of EWS-Fli1 Oncogenic Fusion Protein, Journal of Biological Chemistry, vol.278, issue.17, pp.15105-15115, 2003. ,
DOI : 10.1111/j.1749-6632.1999.tb09415.x
EWS-FlI1, EWS-ERG, and EWS- ETV1 oncoproteins of Ewing tumor family all suppress transcription of transforming growth factor beta type II receptor gene, Cancer Res, vol.60, pp.1536-1540, 2000. ,
EWS/FLI-1 Silencing and Gene Profiling of Ewing Cells Reveal Downstream Oncogenic Pathways and a Crucial Role for Repression of Insulin-Like Growth Factor Binding Protein 3, Molecular and Cellular Biology, vol.24, issue.16, pp.7275-7283, 2004. ,
DOI : 10.1128/MCB.24.16.7275-7283.2004
Downstream EWS/FLI1 - upstream Ewing's sarcoma, Genome Medicine, vol.2, issue.1, p.8, 2010. ,
DOI : 10.1186/gm129
URL : https://genomemedicine.biomedcentral.com/track/pdf/10.1186/gm129?site=genomemedicine.biomedcentral.com
EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells., Journal of Clinical Investigation, vol.99, issue.2, pp.239-247, 1997. ,
DOI : 10.1172/JCI119152
Progress in the Development and Application of Small Molecule Inhibitors of Bromodomain???Acetyl-lysine Interactions, Journal of Medicinal Chemistry, vol.55, issue.22, pp.9393-9413, 2012. ,
DOI : 10.1021/jm300915b
Place your BETs: the therapeutic potential of bromodomains, Trends in Pharmacological Sciences, vol.33, issue.3, pp.146-153, 2012. ,
DOI : 10.1016/j.tips.2011.12.002
Brd4 Recruits P-TEFb to Chromosomes at Late Mitosis To Promote G1 Gene Expression and Cell Cycle Progression, Molecular and Cellular Biology, vol.28, issue.3, pp.967-976, 2008. ,
DOI : 10.1128/MCB.01020-07
URL : http://mcb.asm.org/content/28/3/967.full.pdf
BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma, Clinical Cancer Research, vol.20, issue.4, pp.912-925, 2014. ,
DOI : 10.1158/1078-0432.CCR-13-2281
BET Bromodomain Inhibition as??a Therapeutic Strategy to Target c-Myc, Cell, vol.146, issue.6, pp.904-917, 2011. ,
DOI : 10.1016/j.cell.2011.08.017
URL : https://doi.org/10.1016/j.cell.2011.08.017
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia, Nature, vol.461, issue.7370, pp.529-533, 2011. ,
DOI : 10.1038/nature08448
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia, Nature, vol.41, issue.7370, pp.524-528, 2011. ,
DOI : 10.2144/000112297
Runx2, A multifunctional transcription factor in skeletal development, Journal of Cellular Biochemistry, vol.97, issue.1, pp.1-8, 2002. ,
DOI : 10.1073/pnas.180309597
Oncogenic cooperation between PI3K/Akt signaling and transcription factor Runx2 promotes the invasive properties of metastatic breast cancer cells, Journal of Cellular Physiology, vol.71, issue.8, pp.1784-1792, 2013. ,
DOI : 10.1158/0008-5472.CAN-10-2603
Comparative drug screening in NUT midline carcinoma, British Journal of Cancer, vol.16, issue.5, pp.1189-1198, 2014. ,
DOI : 10.1038/nature10334
URL : http://www.nature.com/bjc/journal/v110/n5/pdf/bjc201454a.pdf
BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD, Molecular Cancer Therapeutics, vol.13, issue.10, pp.2315-2327, 2014. ,
DOI : 10.1158/1535-7163.MCT-14-0258
Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non-Small Cell Lung Cancer, Clinical Cancer Research, vol.19, issue.22, pp.6183-6192, 2013. ,
DOI : 10.1158/1078-0432.CCR-12-3904
BET bromodomain inhibitors?a novel epigenetic approach in castrationresistant prostate cancer, Cancer Biol Ther, vol.15, pp.1583-1585, 2014. ,
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers, Cell, vol.153, issue.2, pp.320-334, 2013. ,
DOI : 10.1016/j.cell.2013.03.036
Convergence of Developmental and Oncogenic Signaling Pathways at Transcriptional Super-Enhancers, Molecular Cell, vol.58, issue.2, pp.362-370, 2015. ,
DOI : 10.1016/j.molcel.2015.02.014
Epigenome Mapping Reveals Distinct Modes of Gene Regulation and Widespread Enhancer Reprogramming by the Oncogenic Fusion Protein EWS-FLI1, Cell Reports, vol.10, issue.7, pp.1082-1095, 2015. ,
DOI : 10.1016/j.celrep.2015.01.042
Selective inhibition of BET bromodomains, Nature, vol.4, issue.7327, pp.1067-1073, 2010. ,
DOI : 10.1016/S0002-9440(10)63049-0
Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma, Oncotarget, vol.7, issue.2, pp.1451-63, 2016. ,
DOI : 10.18632/oncotarget.6385
Sequence-Specific Knockdown of EWS-FLI1 by Targeted, Nonviral Delivery of Small Interfering RNA Inhibits Tumor Growth in a Murine Model of Metastatic Ewing's Sarcoma, Cancer Research, vol.65, issue.19, pp.8984-8992, 2005. ,
DOI : 10.1158/0008-5472.CAN-05-0565
Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes, Cell, vol.153, issue.2, pp.307-319, 2013. ,
DOI : 10.1016/j.cell.2013.03.035
URL : https://doi.org/10.1016/j.cell.2013.03.035
The EWS/FLI1 oncogenic transcription factor deregulates GLI1, Oncogene, vol.79, issue.23, pp.3282-3291, 2008. ,
DOI : 10.1038/sj.onc.1204133
URL : http://www.nature.com/onc/journal/v27/n23/pdf/1210991a.pdf
MAPK/ERK Signaling in Osteosarcomas, Ewing Sarcomas and Chondrosarcomas: Therapeutic Implications and Future Directions, Sarcoma, vol.39, issue.2, p.404810, 2012. ,
DOI : 10.1111/j.1365-2559.2005.02266.x
URL : https://doi.org/10.1155/2012/404810
Interference with the constitutive activation of ERK1 and ERK2 impairs EWS/FLI-1-dependent transformation, Oncogene, vol.19, issue.39, pp.4523-4530, 2000. ,
DOI : 10.1200/JCO.1996.14.4.1245
Identification of an Inhibitor of the EWS-FLI1 Oncogenic Transcription Factor by High-Throughput Screening, JNCI: Journal of the National Cancer Institute, vol.31, issue.4, pp.962-978, 2011. ,
DOI : 10.1002/1097-0142(197304)31:4<889::AID-CNCR2820310419>3.0.CO;2-H
A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma, Nature Medicine, vol.105, issue.7, pp.750-756, 2009. ,
DOI : 10.1038/nm.1983
Ecteinascidin 743 Interferes with the Activity of EWS-FLI1 in Ewing Sarcoma Cells, Neoplasia, vol.13, issue.2, pp.145-153, 2011. ,
DOI : 10.1593/neo.101202
What are super-enhancers?, Nature Genetics, vol.8, issue.1, pp.8-12, 2015. ,
DOI : 10.1126/science.1247005
Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway, Journal of Clinical Investigation, vol.121, issue.1, pp.148-160, 2011. ,
DOI : 10.1172/JCI42874DS1
The dual inhibitory effect of thiostrepton on FoxM1 and EWS/FLI1 provides a novel therapeutic option for Ewing???s sarcoma, International Journal of Oncology, vol.43, issue.3, pp.803-812, 2013. ,
DOI : 10.3892/ijo.2013.2016
NR0B1 Is Required for the Oncogenic Phenotype Mediated by EWS/FLI in Ewing's Sarcoma, Molecular Cancer Research, vol.4, issue.11, pp.851-859, 2006. ,
DOI : 10.1158/1541-7786.MCR-06-0090
Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas, British Journal of Cancer, vol.84, issue.12, pp.1610-1615, 2001. ,
DOI : 10.1054/bjoc.2001.1837